Hepatocellular Carcinoma Clinical Trial
Official title:
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC
This trial is a phase II, single arm, open-label, single center study to assess a
reduced-intensity conditioning regimen, bone marrow transplantation and high dose PTCy in
recipients of a partial liver allograft from a Human Leukocyte Antigen (HLA)-matched or
-haploidentical living related donor in patients with HCC.
The primary objective of this trial is to characterize recurrence-free survival at 1 year
following bone marrow transplantation among recipients of prior partial liver transplantation
from the same donor.
The purpose of this study is to characterize the safety and anti-tumor efficacy of sequential
partial liver transplantation followed by bone marrow transplantation from the same living
related donor. This treatment applies to patients whose cancer remains confined to the liver
but is too widespread to be removed by surgery or treated by a liver transplant from a
deceased donor. The purpose of this combined treatment is to reduce the risk of the cancer
coming back after the liver transplant The bone marrow transplant may reduce the risk of
cancer relapse in two ways. First, patients who have combined bone marrow and solid organ
transplants may be able to get off all anti-rejection drugs, which inhibit the immune system
from destroying cancer cells. Second, the donor's bone marrow contains cells of the immune
system, which can attack any cancer cells that remain after the liver transplant.
This trial is a phase II, single arm, open-label, single center pilot study to assess a
reduced-intensity conditioning regimen, bone marrow transplantation and high dose
post-transplantation cyclophosphamide (PTCy) in recipients of a partial liver allograft from
a Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor in patients
with HCC. The trial includes analyses of tumor characteristics and the number and phenotype
of tumor infiltrating lymphocytes in the explanted tumor. The trial also includes periodic
monitoring of circulating hepatocytes to correlate with tumor response.
The study is expected to take two years to complete accrual of six patients, and the primary
objective of this trial is to characterize recurrence-free survival at 1 year following bone
marrow transplantation among recipients of prior partial liver transplantation from the same
donor. Secondary objectives include documenting percentage of patients who become tolerant of
the transplanted liver, i.e. off immunosuppression for >6 months without biochemical evidence
of liver rejection, and characterizing the relationship between donor chimerism and
transplantation tolerance.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
| Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
| Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
| Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
| Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
| Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
| Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |